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Trastuzumab, a humanized monoclonal antibody against the 
extracellular domain of human epidermal growth factor receptor 
2 (HER-2) prolongs disease-free survival (DFS) and overall 
survival (OS) in patients with early-stage breast cancer (BC). 
Although it is generally well tolerated, it has been associated 
with cardiotoxicity, mainly manifest as a reduction of left-
ventricular ejection fraction (LVEF), especially if the patient has 
received anthracyclines. 
It is generally known that a drop in LVEF has limited diagnostic 
ability. Therefore, the identification of serum biomarkers of 
cardiotoxicity, able to detect damage at an earlier phase, has 
become ideal.  
Troponins (conventional and high-sensitive), natriuretic 
peptides, reactive C protein (CRP), myeloperoxidase (MPO), etc 
are molecular markers which have been assessed to determine 
their role in the detection of treatment induced cardiotoxicity 
(CTIC) with controversial results.  
Objective: This systematic review will synthesize available 
evidence assessing the role of different serum biomarkers in early 
prediction of cardiotoxicity in BC patients treated with adjuvant 
trastuzumab.  
Methods/Design: A systematic review was conducted according 
to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) recommendations. Distinct scientific 
databases such as Google Scholar, Pubmed, EBSCOhost, and 
PsycINFO were searched to aid in the investigation of the 
research problem. 
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Breast cancer (BC) is the most frequent cancer in women. Significant 
improvements in its detection and treatment have led to   improvements in 
disease free survival (DFS) and overall survival (OS) (1). However, reduction in 
cardiac function during treatment with drugs such as anthracyclines and 
trastuzumab prompt treatment interruptions placing patients at higher risks of 
recurrence (1). Although the BC International Group (BCIRG 006) trial showed 
a tendency to better DFS with a regimen containing anthracyclines and 
trastuzumab in Her-2 positive BC, when compared to a regimen without 
anthracyclines, this was not statistically significant and it came with a higher risk 
of cardiotoxicity. The group treated with anthracyclines and trastuzumab, had 
five times as many cases of congestive heart failure (CHF) as the group without 
anthracyclines (2% versus 0.4%) and this was statistically significant (2). 
Anthracyclines and trastuzumab may independently produce cardiomyopathy. 
Moreover, the use of sequential trastuzumab may interfere with the repair of 
anthracyclines cardiac damage. As such, concurrent or sequential treatment with 
anthracyclines and trastuzumab have higher risks of cardiac issues (3). 
Nevertheless, the American Society for Clinical Oncology (ASCO), European 
Society for Medical Oncology (ESMO) and the National Comprehensive Cancer 
Network (NCCN) guidelines recommend the use of sequential treatment, with 
anthracyclines followed by trastuzumab in high risk BC patients (4-6) 
Randomized clinical trials (RCT) and observational studies of 
patients with early BC receiving adjuvant trastuzumab were 
eligible for inclusion. Two investigators have independently 
evaluated those studies and used standardized data extraction 
templates to collect data on the study and patients’ 
characteristics.  
Results: Eleven articles were selected, one RCT and ten 
observational studies. The most studied biomarker was N-
terminal-pro-brain natriuretic peptide (NT-proBNP) followed by 
troponins. Findings showed that NT-proBNP was not predictive 
of CTIC while conflictive results were seen with troponins.  
One study showed a predictive role of high-sensitive (hs) CRP 
and another found a relationship with the levels of MPO.  
Conclusion: Biomarkers offer a unique potential to improve the 
effectiveness and safety of trastuzumab through timely detection 
of CTIC and prompt initiation of appropriate treatment. 
Troponins I and T have shown a predictive role in early 
detection of CTIC but further research would be needed to 
enable more insight and improve the overall patient outcome 
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Therefore, early detection of cardiotoxicity may be a useful strategy by 
enabling early initiation of cardioprotective measures including medications. 
Currently, the standard method for detection of cardiotoxicity have involved 
serial determination of LVEF. But this is a parameter that when reduced is  late 
evidence of myocardial damage, reducing the possibility of recovery(7). 
It is in this area of need that cardiac biomarkers have shown potential in the 
detection of early   treatment induced cardiotoxicity (CTIC) (8,9). 
Several studies have suggested that elevations in conventional troponins 
(cTns) are frequent in patients who received anthracyclines and/or trastuzumab 
and that these elevations predict the development of CTIC. However, the results 
have been inconsistent between studies mainly due to different study designs and 
the lack of standardized reference ranges (8,9). 
Nonetheless, recent ESMO guidelines recommend their use for high-risk 
patients and those receiving high doses of cardiotoxic treatments such as 
anthracyclines(10). 
There are many studies of cardiac biomarkers in patients receiving 
antineoplastic therapies in a range of settings, mostly that of advanced disease. 
However, not many studies have focused solely on   adjuvant treatment for 
patients with Her-2 positive BC. Therefore, this systematic review has been 
undertaken to identify the utility of the most used serum biomarkers to detect 




Material and methods  
 
This systematic review was conducted according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (11). 
This study was performed in accordance with an established protocol.  
 
 
Eligibility and exclusion criteria  
 
We included randomised and non-randomised studies carried out in patients 
with early Her-2 positive BC, who received adjuvant trastuzumab and contained 
serial measurements of cardiac biomarkers and serial LVEF monitoring by 
echocardiograms.  
Studies were ineligible if those included metastatic or advanced cases or any 
patients whose trastuzumab was used as neoadjuvant, case reports, articles 
presented only as an abstract and not fully published, regimens containing other 
targeting drugs in addition to trastuzumab.  
 
 
Literature search strategy 
 
A systematic literature review was conducted to identify studies published 
between 2010 and 2019. Bibliographic searches were carried out on databases of 
Google Scholar, Pubmed, MEDLINE, Trip Medical, EMBASE/EBSCOhost, 
CINAHL, ClinicalKey, BMJ Journals, Cochrane Library and PsycINFO using the 
following terms: BC, early BC, breast neoplasms, Her-2 positive, cardiac 
biomarkers, biomarkers, cardiac dysfunction, cardiac event, early detection.   
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To obtain the required outcome comprehensively, a series of keywords 
combinations was used as well: {role/use of + cardiac biomarkers + early 
detection of cardiotoxicity + early BC HER- 2 positive + treatment with 
trastuzumab}. 
Article selection was based on the examination of cardiac biomarkers used to 




Selection of studies 
 
Initially a thorough search was carried out with the help of Sian Hudson, 
Bournemouth, UK: East Dorset Library and Knowledge Service. Two authors 
independently screened all the retrieved articles for eligibility through the 
examination of the title and abstracts to determine relevance with the subject. 
All duplicates were removed as well as editorials, commentaries and reviews or 
articles referring to cancers other than breast or referring to cases where the aim 
of the treatment was not adjuvant. 
The full text of potentially eligible articles was assessed again by two different 
authors independently. In case of disagreement, the final decision was made by 
discussion and consensus.  
All excluded articles were recorded and reasons for exclusion explained.  
 
 
Data extraction  
.   
Data extraction was also made by the same two authors independently and 
the following data were collected from each article: (a) study characteristics 
(year, country of publication, study design, sample size, type of biomarkers 
measured, definition of cardiac event); (b) characteristics of the study population 
(age, previous anthracyclines exposure, other cardiac risk factors present at 
baseline); (c) the evolution of the different biomarkers in the whole population 
and the differences in both populations, those  who developed cardiotoxicity and 
those  that did not.  
Outcome extraction included the relationship between the increase in 
biomarkers and the development of trastuzumab-related cardiac dysfunction 




The quality of the studies was assessed using the already published Newcastle-
Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-
analyses and the Cochrane collaboration modified tool for assessing risk of bias 
for RCTs (12,13). 
Quality appraisal was performed by two researchers and the disagreements 
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The systematic review process yielded 1572 Studies that seemed relevant to 
this review. Seventy-six additional records were also identified.  
The selected articles were then analysed for any duplicates, leading to the 
removal of 1357 articles. The remaining articles were screened to eliminate the 
ones that had no conformity to the topic, publication issues, lack of proper 
participant selection, and design issues. The screening process led to the 
elimination of 173 articles (Figure 1). 
142 articles then underwent eligibility test to examine it they met the 
inclusion and exclusion criteria and an additional 131 were eliminated. Thus, only 
11 articles met the threshold set for the systematic review, one randomized 
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Quality assessment     
 
This was carried out as described in the methods section. All the studies 
included were categorised as good based on the Newcastle-Ottawa-Scale scores for 
the quality assessment of including studies (Table 1). 
 
Table 1: Quality assessment of the studies included 
Studies included Selection Comparability Outcome Total of stars Quality Rate 
Fallah-Rad et al 
2011 
*** * *** 7 Good 
Sawaya et al 2011 *** * ** 6 Good 
Sawaya et al 2012 *** * ** 6 Good 
Onitilo et al 2012 *** * ** 6 Good 
Katsurada et al 
2014 
*** * *** 7 Good 
Ky et al 2014 *** * ** 6 Good 
Putt et al 2015 *** * ** 6 Good 
Zardavas et al 
2017 
**** * *** 8 Good 
El-Sherbeny et al 
2018 
*** * *** 7 Good 
Matos et al 2016 *** * *** 7 Good 
Goel et al 2019 *** * ** 6 Good 
Newcastle-Ottawa-Scale scores for the quality assessment of including studies. 
 
Studies and patients’ characteristics 
 
Studies and patients’ characteristics are included on Table 2. The majority of 
the studies included are observational studies with only one RCT.  
The studies were carried out in different countries with most of them being 
multicentre. All were prospective in design.  
The median follow-up period ranged from 6 to 15months. The number of 
participating women with early BC HER-2 positive in each study varied from 20 
to 533 with a total number of women included of 1212 patients. The total 
population age range was from 24 to 77 years, although El-Sherbeny et al only 
included patients from 30 to 60 years.  
1117 patients had received anthracyclines before trastuzumab (92.16%) and 
205 developed CTIC (16.91%). 
 
Cardiac risk factors  
 
Not all the studies included reported cardiac risk factors. Hypertension was 
not reported in one study, likewise for Diabetes Mellitus (DM) and 
hyperlipidemia.  
Smoking was not reported in 3 of the studies and the presence of coronary 
artery disease (CAD) was not included in 7 of the studies.  
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O – observational study, A – doxorubicin, E – epirubicin, AC – doxorubicin/cyclophosphamide, P – paclitaxel, H – Trastuzumab, Tax – 
taxanes (either docetaxel or P), anthra – anthracyclines (either A or E), FEC – fluorouracil/E/cyclophosphamide), w – weekly, 3w – 3 weekly, 
S – single centre; M – multicenter, CREC - Cardiac Review and Evaluation Committee, NYHA – New York Heart Association 
 
 
Table 3: Patients cardiovascular risk factors   
Studies Evaluables 
pts  






Rad et al 
2011 
42 5 6 15 4 7 NS 
Sawaya et 
al 2011 
43 12 8 1 6 NR NS 
Sawaya et 
al 2012 
81 26 1 18 6 NR NS 
Onitilo et 
al 2012 
49 17 6 17 31 5  
Katsurada 
et al 2014 
19 2 0 4 6 1  
Ky et al 
2014 
78 21 1 18 NR NR  
Putt et al 
2015 
78 21 1 18 NR NR  
Zardavas 
et al 2017 
452 NR NR NR 48 NR  
El-
Sherbeny 
et al 2018 
61 22 7 15 5 NR  
Matos et 
al 2016 
92 27 4 9 NR NR  
Goel et al 
2019 
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Table 4: Studies according to biomarker 
Biomarker Number of studies Number of patients 
NT-proBNP 10 1163 
TnT 3 711 
TnI 2 501 
hsTnT 1 19 
hsTnI 3 140 
usTnI 2 159 
CRP 2 120 
BNP 1 49 
hsCRP 2 68 
 
All the studies assessed biomarkers serially before initiation of trastuzumab 
and generally every three months while on treatment (Table 5 and 6). 
 
Table 5: Determination of biomarkers timing 
Study Before 
chemotherapy 
Completion of anthra 
(at 3m)/before 
Trastuzumab 
Every 3 months Total period 
Fallah-Rad et al 2011 X X X 12m 
Sawaya et al 2011 X X  At 6m 6m 
Sawaya et al 2012 X X X 15m 
Onitilo et al 2012 X (in 24) X 3 weeks 12m 
Katsurada et al 2014 X X X 15m 
Ky et al 2014 X X X 15m 
Putt et al 2015 X X X 15m 
Matos et al 2016 No X 4, 8, 12 12m 
Zardavas et al 2017 no X 3, 6, 12, 18, 24, 30, 36m  
El-Sherbeny et al 
2018 
X X X 15m 
Goel et al 2019 X X No further analyses 
included 
12m 
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Table 6: Studies and results 
Studies CTIC per 
study 
definition 








No changes _ No 
Sawaya et al 2011 9/43 (21%) Elevation of hsTnI after AC predictive of CTIC  hsTnI Yes 
Sawaya et al 2012 26/81 
/(32%) 
Elevated usTnI after AC predictive if combined 
with peak systolic longitudinal myocardial 
strain 
usTnI Yes 
Onitilo et al 2012 14/49 
(28.6%) 
hsCRP predictive  hsCRP Yes 




hs-TnT at 3 and 6m predictive hsTnT Yes 
Ky et al 2014 23/78 
(24%) 
Elevation usTnI at 3m associated with CTIC usTnI Yes 
Putt et al 2015 23/78 
(29%) 
MPO associated with CTIC MPO Yes 




TnT and TnI predict CTIC TnT, TnI Yes 




NT-proBNP did not predict _ No 
Matos et al 2016 22 (23.9%) NT-proBNP did not predict _ No 
Goel et al 2019 18 (8.3%) Biomarkers did not predict _ No 
 
 
CTIC: definitions used 
 
The definitions of CTIC are heterogeneous and those are included in table 7. 
All the studies used at least echocardiography as a tool to serially evaluate 
LVEF.  
Five studies used the CREC (Cardiac Review and Evaluation Committee) 
definition for the end point.  
The majority of the studies considered a significant decline of LVEF as a 


















Table 7: CTIC definitions 
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y as per 
study 
definition 
Definition CTIC Reduction of 
LVEF 
Symptoms/Sign








Decline LVEF ≥10% to 
below 55% + 
signs/symptoms CHF 
≥10% to < 55% Yes 10 
Sawaya et al 
2011 
9/43 (21%) CREC ≥ 5% to < 55% Yes 9 
≥10% to < 55% No 




CREC ≥ 5% to < 55% Yes 26 
≥10% to < 55% No 
Onitilo et al 2012 14/49 
(28.6%) 
Decline LVEF ≥15% from 
baseline or to <50% 
≥15 
Or  to < 50% 
not needed 14 




CREC ≥ 5% to < 55% Yes 9 
≥10% to < 55% No 
Ky et al 2014 23/78 
(24%) 
CREC ≥ 5% to < 55% Yes 23 
≥10% to < 55% No 
Putt et al 2015 23/78 
(29%) 
CREC ≥ 5% to < 55% Yes 23 
≥10% to < 55% No 
Def alternative 
≥10% to < 50% 
No 




Symptomatic CHF + 
significant decline LVEF 
(NYHA III, IV)  
Decline LVEF 
asymptomatic or mildly 
symptomatic (NYHA I, II) 
Analysis only for secondary 
end-point 
regardless Yes 3 
≥10% to < 50% No/mild 30 




Decline LVEF ≥10% to 
below 55% with/ without 
signs/symptoms of CHF 
 not needed 18 
Matos et al 2016 22/92 
(23.9%) 
Clinical signs/symptom 
CHF or a decline in LVEF 
≥10%  if no symptoms 
regardless Yes 0 
≥10% No 22 
Goel et al 2019 18/217 
(8.3%) 
NYHA class III or IV CHF 
or  
asymptomatic 
decrease LVEF >15% or 
symptomatic decrease 
LVEF >10% to absolute 
value <50%. 
regardless Yes 18 
>15% No 
>10% to <50% No 
CREC – Cardiac Review and Evaluation Committee, NYHA – New York Heart Association 
 
Five of the studies included in this systematic review defined CTIC following 
the CREC as a reduction in LVEF of ≥10% to < 55% without symptoms of heart 
failure (CHF) or a decline of LVEF ≥ 5% to < 55% with symptoms/signs of 
CHF.  
Other studies considered a reduction in LVEF of 10% to ≥15 or any reduction 
<50% with or without symptoms/signs of CHF or patients showing symptoms or 
signs of CHF regardless the LVEF.  
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Incidence of CTIC 
The overall incidence of cardiotoxicity was 12.0% with 95% confidence 
interval (CI) of 11.3% to 12.9%. A total of 205 patients (out of 1212 patients) 
experienced CTIC; unfortunately, only a few studies reported how many patients 
developed symptoms/signs of CHF or how many were asymptomatic (i.e., a 
decline in LVEF without any signs or symptoms of CHF).  
None of the patients died due to cardiac toxicities associated to trastuzumab 
(follow up period 3-15 months).  
 
 
Biomarkers determinations    
 
Again, we can see a significant heterogeneity in terms of the threshold values 
for abnormality in different studies as shown in tables 8 and 9 and also in the 
assays used to make the determinations. 
 






TnT levels - third-generation Roche Elecsys assay (Roche Diagnostics, Inc., Indianapolis, Indiana). 
CRP levels - Immage 800 (Beckman Coulter, Brea, California) antigen-antibody precipitant rate reaction.  
NTpro-BNP levels - electrochemiluminescence sandwich immunoassay (Elecsys ProBNP, Roche 
Diagnostics) Roche 2010 system. 
Sawaya et al 
2011 
Dimension Vista 500 Intelligent Laboratory System (Siemens Healthcare Diagnostics, Deerfield, Illinois), 
using a 1-step, 
homogenous, sandwich chemiluminescent immunoassay based on LOCI technology (Siemens Healthcare 
Diagnostics, Deerfield, Illinois).  
Sawaya et al 
2012 
Troponin I - research-phase highly sensitive assay based on LOCI technology and run on a Dimension 
Vista 1500 System (Siemens Healthcare Diagnostics, Deerfield, IL).  
NT-proBNP - Dimension Vista 500 Intelligent Laboratory System (Siemens Healthcare Diagnostics).  
ST2 - research use only assay (Presage ST2, Critical Diagnostics, San Diego, CA) on an automated 
enzyme linked–immunosorbent assay platform. 
Onitilo et al 
2012 
BNP - Triage_ BNP Test (Inverness Medical, Princeton, NJ)  
hs-CRP - latex-enhanced nephelometry 
TnI Dimension Vista assay (Siemens Healthcare Diagnostics, Deerfield, IL)  
Katsurada et 
al 2014 
hs-TnT, hs-CRP and NTproBNP – electrochemiluminescence immunoassay, latex-enhanced nephelometry, 
and an electrochemiluminescence sandwich immunoassay (Roche Diagnostics, Mannheim, Germany). 
hs-TnI - chemiluminescence sandwich immunoassay according to the manufacturer’s instructions (Siemens 
Medical Solution Diagnostics, Tarrytown NY, USA) 
Ky et al 2014 usTnI and NT-proBNP -  Dimension Vista 500 Intelligent Laboratory System (Siemens Healthcare 
Diagnostics, Deerfield, Illinois) using a 1-step, homogeneous, sandwich chemiluminescent pre-commercial 
immunoassay on the basis of Loci technology.  
hsCRP - Architect immunoassay (Abbott Laboratories, Abbott Park, Illinois).  
Putt et al 
2015 
hs-TnI - research prototype assay 
NT-proBNP - Dimension Vista 500 Intelligent Laboratory System (Siemens Healthcare Diagnostics);  
hsCRP  - Architect immunoassay (Abbott Laboratories) 
Zardavas et 
al 2017 
TnI - ADVIA Centaur XP platform (Siemens Healthcare Diagnostics, Tarrytown, NY) using the cTnI 
Ultra (Tnl-Ultra) assay 
TnT – hsTnT - Elecsys platform (Roche Diagnostics, Manheim, Germany) Cobas E411  
NT-proBNP - Elecsys NT-proBNP assay on the Elecsys platform. 
El-Sherbeny 
et al 2018 
NT-proBNP levels - Human NT-proBNP, ELISA Kit Catalog No: E0485 h (EIAab Science Co.Ltd). 
Matos et al 
2016 
NT-proBNP - electrochemiluminescence immunoassay (ECLIA) on Cobas e411 analyser (Roche 
Diagnostics GmbH, Mannheim, Germany).  
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CTIC and biomarkers  
 
Biomarkers evaluated covered different molecules: troponins (TnT, hsTnT, 
TnI, usTnI, hsTnI), CRP, BNP, NT-proBNP and MPO.  
The most commonly studied biomarker was NT-proBNP followed by TnT.  
 
CRP, hsCRP 
Four studies evaluated CRP and hsCRP with variable results again.  
When CRP was measured, no changes were detected. However, when a more 
sensitive test was carried out (hsCRP), one of the studies showed this to be a 
predictive factor, while the other did not show any significance.  
Ky et al 2014, only reported variations between baseline and visit 2 (both 
before trastuzumab starts), which unfortunately is not representative of CTIC 
but related to anthracyclines toxicity, which may have an impact on future 
CTIC.  
Goel et al 2019, only assessed data as well from the first two visits making 
difficult to draw any conclusions as to the role of biomarkers in predicting CTIC.  




Finally, Putt et al 2015, were the only authors assessing this marker and they 
reported this to be associated with CTIC.  
NT-proBNP 
Ten studies assessed NT-proBNP but none of them proved this to be a 
significant predictor of. Goel et al 2019 reported that although early changes in 
NT-proBNP levels were statistically linked to the development of CTIC, this 
association did not pass the multivariate analyses.  
 
TnI, usTnI, hsTnI 
The TnI assays were highly variable. One study assessed conventional TnI 
while 2 studies measured usTnI and another two studies evaluated hsTnI.  
Conventional TnI was found predictive of CTIC if an increase level was 
detected at 3 months or what it is the same, before trastuzumab (Zardavas et al, 
2017).   
When considering usTnI, Sawaya et al 2012 and Ky et al 2014 found that 
when elevated at the end of the anthracyclines (again before trastuzumab), this 
could predict CTIC.  
When assessing hsTnI, Sawaya et al 2011 showed that an elevation before 
trastuzumab is related to the development of CTIC at 6 months.  
 
TnT, hsTnT 
Three studies assessed the conventional form of TnT whereas one evaluated 
hsTnT.  
These found variable results. Zardavas et al 2017 concluded that the 
conventional TnT will predict TIC if elevated before trastuzumab.  
In contrast, Fallah-Rad et al 2011, did not find any significant relationship, 
same to Goel et al 2019.  
Katsurada et al 2014 who assessed hsTnT reported a predictive role when 
elevated at 3 and at 6 months. 
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Table 9: Biomarkers threshold for abnormality 
Studies TnT hsTnT TnI BNP hsCRP CRP NT-
proBNP 
hsTnI usTnI 




    ≥8 mg/l ≥35pmol/l   




 40ng/L    ?   
 Goel et al 2019 ≥3 ng/l.       ?   
Katsurada et al 
2014 
 ≥14pg/mL   ?  ? ≥40pg/mL  
Onitilo et al 2012   0.1ng/mL 200pg/mL 3 mg/L     
Sawaya et al 2011       ≥125pg/ml. >0.015μg/L  
Ky et al 2014      ? ?  ? 
Sawaya et al 2012       >125pg/mL  >30 
pg/mL 
Putt et al 2015       ? 3 ng/L  
El-Sherbeny et al       ?   





Researchers have long endeavoured  to identify a reliable biomarker(s) 
predictive of CTIC. Many studies have assessed  changes in biomarker levels after 
being exposed to cancer treatment, aiming at exploring whether those changes 
could identify patients at high risk of CTIC or detect early CTIC.  
Reductions in cardiac function can lead to treatment delays and interruptions 
in the short term, and mortality in the long term, especially in patients with 
other cardiovascular risk factors (1). 
Cardio-specific biomarkers are proteins released into the bloodstream by 
injury to heart cells. Conventional Tn and natriuretic peptides (BNP, NT-
proBNP) are the most widely studied within this group.  
Cardiac Tn are released after cardiomyocyte damage induced by different 
mechanisms such as ischemia, oxidative stress  caused by anthracyclines, 
inflammation or apoptosis. (1,2)  
Anthracyclines’ induced CTIC has been reported in up to  6% of cases as 
being clinically relevant and in a further 18% of subclinical CTIC. This is dose 
dependent with higher severity  with higher doses. (14) 
In addition, anthracyclines have a synergistic effect with radiation and 
trastuzumab in terms of CTIC(15). 
This systematic review  focuses only on those cases of adjuvant sequential 
treatment with anthracyclines and trastuzumab.  
There are two different patterns of CTIC linked to trastuzumab depending on 
the timing of anthracyclines administration. In patients receiving only 
trastuzumab, CTIC is not dose dependent and is reversible with cardioprotection 
therapy and stopping trastuzumab.  After cardiac recovery, a re-challenge is 
generally well tolerated(16). 
However, in patients treated concurrently with anthracyclines or sequentially 
after, CTIC and symptomatic CHF can appear in 28% and 27% of patients, 
respectively (17,18). 
The risk of CTIC reduces with longer intervals between both treatments, with 
an incidence of 4.3% with intervals longer than 90 days (19). 
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In this scenario the use of biomarkers able to evidence subclinical CTIC would 
be of extreme importance, not only because it will allow physicians to promptly 
initiate cardiac treatment but also to make the more informed decisions about 
treatment duration.  
Tn are the best characterised biomarkers to assess anthracycline’s induced 
cardiotoxicity. There are two Tn biomarkers, TnT and TnI and two different 
assays to check them, the old assays and the modern high-sensitive assays  (20). 
The prediction of CTIC seems to be less accurate with cTnT (21) compared 
with cTnI. 
TnI is elevated in 14% of patients treated with trastuzumab monotherapy ,in 
around 33% by anthracyclines (although this proportion increased with the 
cumulative dosage) and the combination of anthracyclines and trastuzumab 
produce elevations in 21-24% of patients (22-26).  
In those patients with elevation of TnI, the pattern of release is associated 
with the risk of LV dysfunction (22,23). 
As such, early elevations after the anthracycline administration (27) and 
persistent high figures after completing anthracyclines are predictive of CTIC 
(28). 
These two findings  were demonstrated by ¬¬¬¬Sawaya et al  in two 
different studies in patients receiving sequential anthracyclines and trastuzumab. 
Those who showed persistent elevation of cTnI/usTnI at the completion of 
anthracyclines and at 3 months, had higher chances of developing CTIC (24,26). 
Baseline levels, on the contrary, do not seem to serve as  predictors. However, 
Kitayama et al reported that for hs-cTn baseline values along with levels 
throughout treatment should be collected to gain reliability. These authors found 
that an hs-TnT increase from baseline to the highest value was significantly 
greater  in patients with CTIC and the integration value had 100% sensitivity 
and specificity with a cut-off at 0.070 ng months/mL (29). 
Some authors went even further and showed that cTnI elevations were 
associated with persistent LVEF reductions while normal levels were linked with 
a transient decline at 3 months and complete recovery at 7 months (22). 
Indeed, Cardinale et al showed that recovery of LVEF in patients receiving 
trastuzumab, was more frequent in those patients who had normal TnI levels 
than in those with elevated figures (100 vs 35%).¬ 
In line with these findings, the absence of detectable cTnI early and one 
month after anthracyclines meant low risk of CTIC (1%) (23) and Cardinale et al 
have suggested the same predictive role for the elevation of cTnI for those 
receiving trastuzumab, (30) indicating that this biomarker might be relevant at 
the time of stratifying patient’s risk.  
Asub study of the HERA trial found that the elevation of cTnI and cTnT at 
the end of anthracyclines predicts CTIC as expected, but the contribution of 
sequential trastuzumab on this risk remained unclear (31). However, it appears 
that anthracyclines might increase the myocardial susceptibility to injury when 
combined with trastuzumab (32,33). 
Recent studies confirmed that by using high-sensitivity assays, cTn elevations 
are even more frequent. However, the link between serial changes in hs-TnI and 
CTIC is not consistent (24,26,30,34-37). 
Ky et al found a relation between early elevated levels of usTnI with CTIC 
but again it is not clear if those findings are related to anthracyclines, 
trastuzumab or the combination of both (36). 
The role of cTnT in the prediction of CTIC is less certain . However, 
Katsurada et al showed that elevated levels of hs-TnT at 6 months had 78% 
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sensitivity and 80% specificity for predicting CTIC at 15 months mindful they 
only included 19 patients (38). 
Grover et al claimed that cTnT was a good marker of CTIC progression (39). 
Significant early functional changes were detected by cardiac MRI and these 
continued for 12 months. These accompanied significant changes in cTnT and 
CRP.  
In contrast with these, other studies could not find any relation between the 
elevations of hsTnI and cTnT respectively and CTIC (37,38). 
Putt et al found a substantial increase in hsTnI levels at 3 months which 
persisted at 15 months even though they could not determine if  this was  a good 
marker for CTIC perhaps due to data missing in a large fraction of patients (38). 
These authors hypothesized that the elevation of hsTnI might evidence damages 
predisposing to CTIC.  
Other studies have reported increased levels of hs-TnT after anthracyclines 
whereas no elevations were seen with trastuzumab. They suggested that this may 
help identify patients at risk, especially when receiving trastuzumab sequentially, 
enabling  early pre-emptive cardioprotective treatments or therapy 
modifications(40). 
Theoretically, the ideal biomarker should detect early CTIC and  should 
overcome the shortcomings linked with cardiac imaging. The biomarkers are not 
subjected to operator variability and interpretation. However, some authors could 
not find a predictive role for these biomarkers in isolation  but when combined 
with other biomarkers or peak systolic myocardial strain (41). 
For example, a study assessing hs-cTnT in patients with non-Hodgkin 
lymphoma suggested that combining this with two-dimensional speckle tracking 
echocardiography increases the sensitivity to detect late-onset CTIC in those 
patients who received anthracyclines (42). Similar observations were made by 
Sawaya et al(34). 
The wide diversity in all these results is readily  explained by the fact that 
different studies include different patient populations, utilised different assays to 
measure biomarkers, variable thresholds, sample sizes, different sample collection 
timings and variable CTIC definitions (43,44). 
Theoretically, hs-Tns will increase the chances of early detection of cardiac 
damage. Nevertheless, other studies have shown an important role of elevated 




Natriuretic peptides  
 
Another biomarker to  have been assessed are the  natriuretic peptides which 
mark cardiac volume and pressure overload. Their role is clear in acute and 
chronic CHF (26) however, their use in predicting CTIC is less clear (24,29). 
It is known that trastuzumab may induce ventricle wall stress, which could 
release NT-proBNP and this could be detected prior to an LVEF decline.  
Studies investigating  the link between NT-proBNP and CTIC in BC patients 
have been  inconclusive  (24,32,34,36,37,46-48). 
Two large prospective studies showed increased NT-proBNP levels in BC 
patients with CTIC (32,46), but other studies did not (24,34,36,37,47,48). 
These studies are constrained by a low incidence of LVEF declines, or 
predominant focus on anthracyclines instead of trastuzumab(46).  
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Bouwer et al concluded that NT-proBNP cannot be used as a marker for 
trastuzumab-induced CTIC but showed that those patients showing a reduction 
in LVEF during anthracyclines, are high risk for further CTIC with trastuzumab.  
Low figures of BNP/NT-proBNP have shown a high negative predictive value 
while high levels indicate CHF. However, these levels may not be as reliable as 
expected in advanced age, renal dysfunction or obesity.  
Cutoff values for acute CHF have been established as <30-50pg/ml of BNP 
and <300pg/ml of NT-proBNP (49,50) but the exact figures to predict CTIC are 
still unknown.  
Lenihan et al reported that among patients receiving anthracyclines who 
developed cardiac events, at least 1 BNP value was elevated at >100 pg/mL 
before the cardiac event, supporting the role of this biomarker as predictive of 
anthracyclines CTIC (51). 
Others have found that baseline levels of NT-proBNP and LVEF decline 
during anthracyclines, were independently associated with CTIC. They even 
showed that for every 10 pmol/l elevation, LVEF declined by around 4% (46). 
Consistent  with this, Demissei et al showed that doubling the levels of NT-
proBNP was linked to a 0.7% decline in LVEF at each subsequent visit. When 
those changes were classified by treatment regimen, it was reported that in those 
receiving anthracycline with trastuzumab, for each NT-proBNP doubling an up 
to 1.3% decline in LVEF was seen. And in those only on trastuzumab, NT-
proBNP levels significantly declined in the first 6 months (52). 
Authors advocated that BNP/NT-proBNP should be added to the basal 
cardiac risk factors as may help predict CTIC and they even suggested thresholds 
of 150 ng/L or 300 ng/L respectively to identify groups with high risk of 
developing CTIC (2 to 3-folds) especially in patients treated with the 
anthracyclines.  
Our systematic review has found ten studies measuring NT-proBNP and one 
checking BNP. None of them showed these biomarkers to be predictive for CTIC 
in adjuvant BC patients with sequential treatment. Only Goel et al found that 
early changes in NT-proBNP levels were statistically correlated with CTIC, but 
this association did not pass the multivariate analyses (40). 
Also the HERA sub study reported higher levels of NT-proBNP following 
anthracyclines and before trastuzumab. However, due to the lack of a definitive 
elevation threshold, they could not conclude any predictive role  (32). 
Romano et al found that NT-proBNP increased in all patients 24h after the 
initiation of chemotherapy. Moreover, patients with normal heart function 
showed normal or transiently high NT-proBNP. However, the levels persisted 
higher in patients with progressively worse heart function during treatment and 
at 3-, 6- and 12-month follow-up (46). 
Similar results were reported by others showing that persistently high levels of 
NT-proBNP after having high dose of chemotherapy, is linked to the 
development of CTIC. (53) 
In any case, the predictive value of these biomarkers is not definitively 
confirmed as prior studies mainly focused on the changes during a short time, 
mostly limited to the time of active therapy.   
Urun et al have shown that a higher level of NT-proBNP is associated with 
CTIC even in patients with preserved baseline LVEF (36) whereas De Iuliis et al 
reported that NT-proBNP was significantly elevated at multiple time points after 
the completion of chemotherapy but there was no significant change in LVEF 
(54). 
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Perik et al found that baseline levels of NT-proBNP were higher in patients 
who develop CHF but this study  included only 17 patients and all metastatic 
BC (55). 
Grover et al observed NT-proBNP was worse than cTnT as a marker of CTIC 
progression (39). 
They found that although CTIC occurred within 4 months, NT-proBNP did 
not change from baseline to that time. The levels of the natriuretic peptide 
stayed elevated at one year after stopping the chemotherapy.  
Of note  the kinetics of BNP/NT-proBNP and cTn release in CTIC  remain 
unknown.  
Ponde et al have suggested that only those treated with anthracyclines 





Other biomarkers such as MPO have been assessed but again results are 
inconsistent. Initially it was considered an attractive biomarker, as the central 
mechanism for anthracyclines induced CTIC is the oxidative stress, and some 
small studies have reported that higher levels of MPO during the treatment are 
associated with a higher risk of CTIC with anthracyclines followed by 
trastuzumab (36,37). 
Ky et al found that among 78 BC patients receiving doxorubicin and 
trastuzumab, an early increase in MPO levels from baseline to 3 months was 
associated with a higher risk of CTIC during the 15-month period of treatment 
(36). 
Putt et al in a later study showed that increases in MPO beyond 3 months of 
chemotherapy still remained predictive of increased CTIC risk over the period of 
treatment(37). 
Recently, Demissei et al showed that elevations of MPO as well as baseline 
levels are linked to a higher risk of CTIC in patients treated with anthracyclines 
followed by trastuzumab (52). 
Another studied biomarker is  C-reactive protein (CRP) which is an acute 
phase reactant, involved in both anti-inflammatory and pro-inflammatory 
responses. It has been used as a marker of risk for cardiovascular disease since the 
1960s. High-sensitivity CRP (hsCRP) is more accurate than routine CRP when 
measuring baseline levels (56). 
Four studies included in this systematic review assessed CRP (two studies) 
and hsCRP (two studies). Only Onitilo et al suggested that abnormal hs-CRP 
has a high sensitivity (92.9 %) and negative predictive value (94.4 %) for reduced 
LVEF, although the specificity is low. These authors concluded that this could be 





This systematic review found eleven studies that apply to BC patients 
receiving adjuvant trastuzumab. The review is limited by the heterogeneity 
between studies with respect to sample sizes, sample collection timing, definition 
of CTIC, limits of detection of assays utilised, interval times between 
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anthracyclines and trastuzumab, the lack of a positive threshold or the use of 
different thresholds of positivity and the low number of cardiac events (27,28).  
Recently, Demissei et al (not included in this review as the study recruited 
metastatic patients as well) have reported the results of a prospective cohort of 
323 patients treated with anthracyclines and/or trastuzumab followed over a 
maximum of 3.7 years with serial echocardiograms (52). 
These authors found early elevations in all biomarkers with anthracyclines and 
reported that hs-cTnT levels >14 ng/L at anthracycline completion were linked 
to a 2-fold increased CTIC risk. Elevations of NT-proBNP and MPO were also 
associated with CTIC in the whole cohort but mostly with sequential 





Circulating serum biomarkers are attractive tools to apply in early detection 
of CTIC, but no single determination seems to be perfect.  
Based on the results of our systematic review, noting its limitations, it seems 
that  
(a) elevations in TnI, hs-TnI, usTnI at completion of anthracyclines or early 
during trastuzumab seem to be associated with CTIC in patients receiving 
sequential anthracyclines and trastuzumab.  
(b) For a long time, it has been known that the prediction of CTIC is less 
accurate with cTnT compared with cTnI. However, Zardavas et al showed for the 
first time, that cTnT elevations seem to be associated with CTIC within those 
patients receiving sequential anthracyclines followed by trastuzumab (32). 
(c) Elevated levels of hs-cTnT specifically at the time of completion of 
anthracyclines and at  6 months seem to predict future CTIC.  
(d) Elevation of MPO throughout the course of adjuvant anthracyclines and 
sequential trastuzumab are associated with CTIC.  
(e) Elevations of NT-proBNP/BNP do not seem to be associated with CTIC 
in this population although the small size and small number of cardiac events in 
these studies limit the statistical power to conclude/exclude a predictive role.   
(f) A multimodality strategy incorporating several biomarkers with cardiac 
imaging might provide higher value in detecting patients at high risk of CTIC. 
In summary, there is a clear need for novel biomarkers able to detect 
myocardial damage earlier than Tn and also for standard strategies for cardio 
protection. With the new anti-Her-2 therapies currently used in adjuvant 
settings, well-designed prospective trials with statistical power and long-term 
follow-up are mandatory to assess these issues and to give clinicians the proper 
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